
Opinion|Videos|February 13, 2025
Exploring Nintedanib and Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis
Author(s)Anthony J. Esposito, M.D.
An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating IPF?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
USPS Woes Continue: Health Plans, Be Prepared
2
Updated: FDA approves first-in-class therapy for metastatic pancreatic cancer
3
FDA approves Tevimbra and Ziihera for HER2-positive gastroesophageal cancer
4
AI-assisted nodule detection could boost early lung cancer diagnosis
5
























